Oral THC Research Is Weighted Toward Capsules and Tablets, Not Every Kind of Edible

A 2020 systematic review found that capsules and tablets were the most commonly studied oral THC formulations. Its pharmacokinetic findings should not be presented as though brownies, oils, teas and pharmaceutical forms all have equally developed evidence.

The formulation was part of the review question

Twenty-six studies met the review's criteria. The evidence covered capsules, tablets, baked goods, oils and decoctions. These categories describe different preparations, and combining them under oral cannabis can obscure the uneven distribution of the research.

Absorption was variable and peaks delayed

The authors described substantial variability in oral THC absorption and later peak plasma concentrations than with other routes. They noted apparently greater variability in some baked-good and oil forms. Those observations do not supply one reliable onset or peak time for every oral product.

Exposure and effect need separate measurement

A plasma concentration curve characterizes exposure in the sampled compartment. It does not independently establish a person's symptom response or functional performance. A formulation-specific pharmacokinetic result therefore cannot become a universal prediction of intoxication duration.

Interpreting the evidence

When comparing oral THC studies, identify the formulation and what was actually measured. This review highlights an evidence imbalance and uncertainty. It does not provide a safe redosing interval, an exact edible-to-inhaled equivalence or a standardized effect timeline for an individual.

Related reading: interpreting cannabis tolerance claims.

Research reference

Lourdes Poyatos; Ana Pilar Pérez-Acevedo; Esther Papaseit; Clara Pérez-Mañá; Soraya Martin; Olga Hladun; Adrià Siles; Marta Torrens; Francesco Paolo Busardo; Magí Farré (2020). Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina. doi:10.3390/medicina56060309.

This discussion draws on the abstract and introductory material in the supplied research synthesis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us